Yozayo In the field of genetic testing and precision medicine, Myriad Genetics (NASDAQ: NASDAQ:MYGN) is a progressive company, which can be observed in its steady double-digit revenue growth and the upward revision of revenue guidance for the next year. The financial results of the third quarter of 2023 of the company demonstrate a strong year-over-year…
SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon – Head, IR Dr. Jurgi Camblong – Co-Founder and CEO Ross Muken – CFO and COO Conference Call Participants Yuko Oku – Morgan Stanley Kyle Boucher – TD Cowen Mark Massaro – BTIG Operator Ladies and…
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo – Senior Vice President, Investor Relations Paul Diaz – President and Chief Executive Officer Mark Verratti – Chief Commercial Officer Bryan Riggsbee – Chief Financial Officer Conference Call Participants Elizabeth Koslosky – Goldman Sachs Andrew Cooper…
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon – IR Ming Hsieh – CEO Brandon Perthuis – CCO Paul Kim – CFO Lawrence Weiss – Chief Medical Officer Conference Call Participants David Westenberg – Piper Sandler Andrew Cooper – Raymond James Operator Hello, and…
ebrublue10/iStock via Getty Images Company Overview Established in 2011, Fulgent Genetics (NASDAQ:FLGT) is a technology-driven organization dedicated to clinical diagnostic and therapeutic advancements. The diagnostic branch of the company provides a wide range of molecular and genetic testing services to improve patient care. On the other hand, their therapeutic division is primarily devoted to creating…